PXS — Pharmaxis Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousMicro CapNeutral
- AU$23.75m
- AU$16.56m
- AU$18.32m
- 29
- 33
- 42
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.53 | ||
| Price to Tang. Book | 2.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -59.73% | ||
| Return on Equity | 20.98% | ||
| Operating Margin | -89.77% | ||
Financial Summary
| Year End 30th Jun | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 50.33 | 12.55 | 12.55 | 22.84 | 14.82 | 17.37 | 19.27 | -3.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharmaxis Ltd (Pharmaxis) is an Australia-based pharmaceutical research company engaged in developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The Company has a productive drug discovery engine, drug candidates in clinical trials and two respiratory products approved in global markets. Its lead drug candidate, PXS-5505, is an orally taken drug that inhibits the lysyl oxidase family of enzymes. Its PXS-5505 is used for the treatment of the blood cancer myelofibrosis, which affects one in 500,000 people. PXS-5505 is also being investigated as a potential treatment for other cancers, such as liver and pancreatic cancer. It also has two respiratory products: Bronchitol and Aridol. Bronchitol is used for the treatment of cystic fibrosis. Its other drugs in development include PXS-5382 (LOXL2 inhibitor), PXS-6302 (topical pan LOX inhibitor), PXS-4728 (SSAO inhibitor), PXS-4699 (dual SSAO/MAOB inhibitor) and PXS-5370 (dual SSAO/MPO inhibitor).
Directors
- Malcolm Mccomas NEC (65)
- Gary Phillips CEO (59)
- David McGarvey CFO (64)
- Brett Charlton OTH (64)
- Wolfgang Jarolimek OTH (56)
- Kristen Morgan OTH (48)
- William Delaat NID (69)
- Neil Graham NID
- Kathleen Metters NID (62)
- Last Annual
- June 30th, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- May 29th, 1998
- Public Since
- November 10th, 2003
- No. of Shareholders
- 4,797
- No. of Employees
- 107
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 718,994,705
- Address
- 20 Rodborough Rd, FRENCHS FOREST, 2086
- Web
- https://www.pharmaxis.com.au/
- Phone
- +61 294547200
- Contact
- David McGarvey
- Auditors
- PricewaterhouseCoopers
Upcoming Events for PXS
Similar to PXS
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
Botanix Pharmaceuticals
Australian Stock Exchange - SEATS
FAQ
What is the Pharmaxis share price?
As of Today at 19:17 UTC, shares in Pharmaxis are trading at AU$0.06. This share price information is delayed by 15 minutes.
How has the Pharmaxis share price performed this year?
Shares in Pharmaxis last closed at AU$0.06 and the price had moved by -32.1% over the past 365 days. In terms of relative price strength the Pharmaxis share price has underperformed the ASX All Ordinaries Index by -36.86% over the past year.
What are the analyst and broker recommendations for Pharmaxis?
The overall consensus recommendation for Pharmaxis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Pharmaxis dividend yield?
Pharmaxis does not currently pay a dividend.
Does Pharmaxis pay a dividend?
Pharmaxis does not currently pay a dividend.
When does Pharmaxis next pay dividends?
Pharmaxis does not currently pay a dividend.
How do I buy Pharmaxis shares?
To buy shares in Pharmaxis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharmaxis?
As of the previous close price of AU$0.06, shares in Pharmaxis had a market capitalisation of AU$39.54m.
Where are Pharmaxis shares listed?
Here are the trading details for Pharmaxis:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PXS
What kind of share is Pharmaxis?
Based on an overall assessment of its quality, value and momentum Pharmaxis is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharmaxis share price forecast for 2023?
The analyst consensus target price for shares in Pharmaxis is AU$0.17. That is 209.09% above the last closing price of AU$0.06.
Analysts covering Pharmaxis currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.02 for the next financial year.
What is the trend in the Pharmaxis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmaxis. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -3.23%.
As of the last closing price of AU$0.06, shares in Pharmaxis were trading -4.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharmaxis PE Ratio?
The Pharmaxis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharmaxis?
Pharmaxis' management team is headed by:
- Malcolm Mccomas - NEC
- Gary Phillips - CEO
- David McGarvey - CFO
- Brett Charlton - OTH
- Wolfgang Jarolimek - OTH
- Kristen Morgan - OTH
- William Delaat - NID
- Neil Graham - NID
- Kathleen Metters - NID